Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer
Fig 5
Impact of rapamycin and Torin1 on constitutively activated mTOR signaling pathway in TSC1 or TSC2 deficient cells.
Cells were treated with Torin1 (250 nM) or rapamycin (20 nM) for 24h. Untreated cells and MGH-U1 were used as controls. Cells were serum starved for 24h (−) or received after starvation serum add back for 30 min (+). Rapamycin and Torin1-treated cells show no expression of pS6K (Thr389) and pS6 (Ser 240/244) in serum absence or stimulated conditions compared to the upregulated expression in untreated cells. pAKT (Ser 473) levels are lower after Torin1 and higher after rapamycin treatment.